GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Alphatec Holdings Inc (NAS:ATEC) » Definitions » Cash Conversion Cycle

Alphatec Holdings (Alphatec Holdings) Cash Conversion Cycle

: 224.97 (As of Dec. 2023)
View and export this data going back to 2006. Start your Free Trial

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Alphatec Holdings's Days Sales Outstanding for the three months ended in Dec. 2023 was 45.35.
Alphatec Holdings's Days Inventory for the three months ended in Dec. 2023 was 285.3.
Alphatec Holdings's Days Payable for the three months ended in Dec. 2023 was 105.68.
Therefore, Alphatec Holdings's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was 224.97.


Alphatec Holdings Cash Conversion Cycle Historical Data

The historical data trend for Alphatec Holdings's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphatec Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 312.30 289.03 250.64 258.67 214.23

Alphatec Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 214.46 211.55 174.41 235.25 224.97

Competitive Comparison

For the Medical Devices subindustry, Alphatec Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alphatec Holdings Cash Conversion Cycle Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Alphatec Holdings's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Alphatec Holdings's Cash Conversion Cycle falls into.



Alphatec Holdings Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Alphatec Holdings's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=50.21+252.83-88.81
=214.23

Alphatec Holdings's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=45.35+285.3-105.68
=224.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alphatec Holdings  (NAS:ATEC) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Alphatec Holdings Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Alphatec Holdings's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Alphatec Holdings (Alphatec Holdings) Business Description

Traded in Other Exchanges
Address
1950 Camino Vida Roble, Carlsbad, CA, USA, 92008
Alphatec Holdings Inc is a medical technology company focused on the design, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.
Executives
David Sponsel officer: EVP, Sales C/O ALPHATEC SPINE, INC., 5818 EL CAMINO REAL, CARLSBAD CA 92008
David M Demski director C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Patrick Miles director, officer: Executive Chairman 7475 LUSK BLVD., SAN DIEGO CA 92121
Tullis James L L director, 10 percent owner 100 FIRST STAMFORD PLACE, STAMFORD CT 06907
David H Mowry director 9775 TOLEDO, IRVINE CA 92618
Evan Bakst director 225 CENTRAL PARK WEST, APT. 1605, NEW YORK NY 10024
Jennifer N. Pritzker 10 percent owner C/O SQUADRON CAPITAL LLC, 104 S. MICHIGAN AVENUE, SUITE 500, CHICAGO IL 60603
Tyson Eliot Marshall officer: GENERAL COUNSEL & CORP. SEC. 10680 TREENA STREET, SUITE 500, SAN DIEGO CA 92131
Craig E Hunsaker officer: See Remarks C/O ALPHATEC HOLDINGS, INC., 5818 EL CAMINO REAL, CARLSBAD CA 92008
Elizabeth Ann Altman director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Paul Segal 10 percent owner 1700 BROADWAY, 35TH FLOOR, NEW YORK NY 10019
L-5 Healthcare Partners, Llc 10 percent owner, other: Director by deputization 1700 BROADWAY, 35TH FLOOR, NEW YORK NY 10019
John Todd Koning officer: Chief Financial Officer C/O MASIMO CORPORATION, 52 DISCOVERY, IRVINE CA 92618
David R Pelizzon director, 10 percent owner 2850 FRONTIER DR, WARSAW IN 46582
Scott Lish officer: SVP, Development C/O ALPHATEC SPINE, INC., 5818 EL CAMINO REAL, CARLSBAD CA 92008